Myovant Sciences Ltd.
MYOVDelisted Mar 10, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001679082
Myovant Sciences Ltd. was delisted on Mar 10, 2023; its insiders filed their last Form 4 on Mar 10, 2023; 118 institutions reported holding it in 13F filings for Q4 2022, worth $1.12B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Myovant Sciences Ltd. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Myovant Sciences Ltd., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sumitomo Pharma Co., Ltd. | 10% Owner | 45,798,176Indirect | Mar 10, 2023 | 0 |
| Sumitovant Biopharma Ltd. | 10% Owner | 45,798,176Indirect | Mar 10, 2023 | 0 |
| Sumitomo Chemical Co., Ltd. | 10% Owner | 45,798,176Indirect | Mar 10, 2023 | 0 |
| Potter Myrtle S | Director | 0 | Mar 10, 2023 | 0 |
| Guinan Mark | Director | 0 | Mar 10, 2023 | 0 |
| Marek David C | Principal Executive Officer | 0 | Mar 10, 2023 | 0 |
| Gulfo Adele M. | Director | 0 | Mar 10, 2023 | 0 |
| Curran Terrie | Director | 0 | Mar 10, 2023 | 0 |
| Lang Matthew | General Counsel & Corp. Secy. | 0 | Mar 10, 2023 | 0 |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | 0 | Mar 10, 2023 | 0 |
| Merendino Lauren | Chief Commercial Officer | 0 | Mar 10, 2023 | 0 |
| Mehra Uneek | Principal Financial Officer | 0 | Mar 10, 2023 | 0 |
| Valente Nancy | Director | 0 | Mar 10, 2023 | 0 |
| Karbe Frank | Principal Fin'l & Accounting | 212,296 | Jul 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2021 (view filing)5:00 PM ET | Aug 30-31 | 2 days | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +109.0K | $24.05 | +$2.62M | +0.2%49.1M after | 2 lots |
| Aug 31, 2021 (view filing) | Aug 27-30 | 4 days | Arjona Ferreira Juan CamiloChief Medical Officer | SSale | −23.0K | $23.93 | −$549.9K | −11.8%171.3K after | 2 lots |
| Aug 30, 2021 (view filing)5:00 PM ET | Aug 26-27 | 4 days | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +77.0K | $22.91 | +$1.77M | +0.2%49.0M after | 2 lots |
| Aug 26, 2021 (view filing)5:00 PM ET | Aug 24-25 | 2 days | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +63.0K | $22.40 | +$1.41M | +0.1%48.9M after | 2 lots |
| Aug 24, 2021 (view filing)5:00 PM ET | Aug 20-23 | 4 days | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +101.9K | $21.65 | +$2.21M | +0.2%48.9M after | 3 lots |
| Aug 20, 2021 (view filing)5:00 PM ET | Aug 18-19 | 2 days | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +63.9K | $21.49 | +$1.37M | +0.1%48.8M after | 2 lots |
| Aug 18, 2021 (view filing)5:05 PM ET | Aug 16-17 | 2 days | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +71.7K | $21.21 | +$1.52M | +0.1%48.7M after | 3 lots |
| Jul 13, 2021 (view filing) | Jul 9 | 4 days | Lang MatthewGeneral Counsel & Corp. Secy. | SSale | −6.95K | $21.52 | −$149.7K | −3.6%186.5K after | |
| Jul 9, 2021 (view filing) | Jul 7 | 2 days | Arjona Ferreira Juan CamiloChief Medical Officer | SSale | −2.78K | $21.75 | −$60.4K | −1.6%173.3K after | |
| Jul 9, 2021 (view filing) | Jul 7 | 2 days | Karbe FrankPrincipal Fin'l & Accounting | SSale | −3.23K | $21.75 | −$70.3K | −1.5%212.3K after |